Roche is looking to snag a $1 billion piece of the lung cancer market for its own, and it now has survival data to back up its bid. More: Roche eyes B-plus Tecentriq nod with small-cell lung cancer survival win
read moreNovartis CEO Vas Narasimhan is seeking to cut the company’s workforce from 124,000 to under 100,000 by 2022 as the company grapples with major marketing and manufacturing issues. More: Novartis, axing 19% of its workforce, faces big challenges with thinned
read morePfizer, which has been working to build back capacity at its troubled Kansas sterile injectables plant, is hoping to add hundreds of employees in the coming weeks. More: Pfizer hiring 350 at Kansas sterile injectables plant Source: fierce
read moreVerastem Oncology has come a long way from the major failure of its lead candidate defactinib to its first FDA approval. And it’s done it with a drug that itself had a troubled past. More: Once-troubled Verastem wins FDA nod for AbbVie-abandoned
read moreGilead and Express Scripts have clashed in hepatitis C before, but now that Gilead plans authorized generics of its own drugs, Express Scripts is praising the move. More: Express Scripts praises, then takes credit for Gilead's authorized generics launches Source:
read moreNovartis has announced plans to close its manufacturing site in Grimsby, UK, by the end of 2020, among a wider job cull likely to affect more than 2,200 positions in the country and Switzerland. More: Novartis to shutter Grimsby site
read more© 1994 - 2026 B.M. Pharmaceuticals